Exenatide: from the Gila monster to the pharmacy.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trials and pharmacology without systematic search or meta-analysis.
PubMed 16529340 · doi:10.1331/154434506775268698
What was done
This narrative review synthesized pharmacology data, manufacturer records, and three pivotal clinical trials evaluating twice-daily exenatide self-injection as add-on therapy in patients with type 2 diabetes mellitus uncontrolled on maximum doses of metformin, sulfonylureas, or both. It also reviewed practical counseling considerations for pharmacists.
What was found
The abstract reports that exenatide add-on therapy produced significant reductions in glycosylated hemoglobin (A1C) compared with placebo, accompanied by weight loss without intentional caloric deficit or exercise counseling. Mild-to-moderate nausea was the most frequent adverse effect, occurring primarily at treatment initiation, decreasing over time, and mitigated by dose titration. The abstract does not provide exact numerical effect sizes, percentage changes, or event rates.
Why it matters
It summarizes the clinical rationale and mechanism of GLP-1 receptor agonism for type 2 diabetes at the time of exenatide's introduction, emphasizing administration timing and side effect management.
Limits
The paper is a narrative overview rather than a systematic review. The abstract omits precise quantitative data, participant numbers, trial durations, and long-term cardiovascular or safety outcomes.
Cited by
- supports Natural GLP-1-like compound exendin-4 was discovered in the saliva of the Gila monster.